# KPI-012 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/kpi-012

> KPI-012, sponsored by KALA BIO, Inc. (KALA): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KPI-012 |
| Codes | KPI-012 |
| Sponsor | KALA BIO, Inc. (KALA) https://sec-api.dev/companies/kala/catalysts |
| Indications | [pced and plans to report topline data](https://sec-api.dev/indications/pced-and-plans-to-report-topline-data) |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Feb 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2025-03-31, last confirmed 2026-04-15.
- SEC Form 10-K (accession 0001104659-26-043782): "In February 2023, we dosed the first patient in the CHASE trial of KPI-012 in patients with PCED in the United States." https://www.sec.gov/Archives/edgar/data/1479419/000110465926043782/kala-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-004081): "In February 2023, we dosed the first patient in the CHASE trial of KPI-012 in patients with PCED in the United States." https://www.sec.gov/Archives/edgar/data/1479419/000155837025004081/kala-20241231x10k.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: PCED and plans to report topline data.
- First seen 2024-11-12, last confirmed 2025-08-08.
- Press release filed with the SEC (EX-99) (accession 0001104659-24-132308): ""With over 80% of enrollment now complete in the CHASE trial, we remain on track to report topline data in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/tm2432193d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010850): "We are now focused on finalizing study activities and remain on track to report topline results at the end of September of this year."" https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015168): "-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -" https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015168): ""We remain focused on advancing patient enrollment in our Phase 2b CHASE trial evaluating KPI-012 for the treatment of PCED and are targeting topline results in the second quarter of 2025," said Mark Iwicki, Chair and Chief Executive Officer of KALA BIO." https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015168): "KALA continues to enroll patients in the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012 for the treatment of PCED and plans to report topline data in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112xex99d1.htm

### Sep 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2. Indication: PCED and plans to report topline data.
- First seen 2025-03-31, last confirmed 2025-08-08.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010850): "-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 --" https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007664): "-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 --" https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007664): "KALA continues to enroll patients in the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012 for the treatment of PCED and is targeting topline data in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004080): "KALA continues to enroll patients in the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012 for the treatment of PCED and plans to report topline data in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007664): ""We are targeting to report topline results from the Phase 2b CHASE trial of KPI-012 in the third quarter of this year, which, if successful could serve as the first of two pivotal trials needed to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010850): "The Company expects to report topline data from the trial at the end of September of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004080): "--Continuing enrollment into 2Q25; currently targeting topline data in 3Q25—" https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004080): "We now plan to report topline results in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331xex99d1.htm
- SEC Form 8-K (accession 0001104659-25-066593): "The Company expects to report topline data from the CHASE trial in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000110465925066593/tm2520099d1_8k.htm
- SEC Form 10-K (accession 0001558370-25-004081): "We are targeting reporting topline safety and efficacy data for the CHASE trial in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1479419/000155837025004081/kala-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-25-010853): "We expect that our research and development costs for 2025 will be comparable to such expenses for the year ended December 31, 2024 as we continue to advance the clinical development of KPI-012, including conducting our ongoing CHASE trial from which we expect to report topline safety and efficacy data at the end of September 2025, and as we conduct any necessary preclinical studies and clinical trials and other development activities for any other product candidate we may develop in the future, including our planned preclinical studies under our KPI-014 program." https://www.sec.gov/Archives/edgar/data/1479419/000155837025010853/kala-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007763): "We expect that our research and development costs for 2025 will be comparable to such expenses for the year ended December 31, 2024 as we continue to advance the clinical development of KPI-012, including conducting our ongoing CHASE trial from which we anticipate reporting topline safety and efficacy data in the third quarter of 2025, and as we conduct any necessary preclinical studies and clinical trials and other development activities for any other product candidate we may develop in the future, including our planned preclinical studies under our KPI-014 program." https://www.sec.gov/Archives/edgar/data/1479419/000155837025007763/kala-20250331x10q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/kpi-012.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KPI-012 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/kpi-012

```bibtex
@misc{secapidev_pdufa_kpi_012_20261116,
  title        = {KPI-012 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/kpi-012}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_kpi_012_20261116","title":"KPI-012 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/kpi-012","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
